Passive Transmission of COVID-19 Antibody From Mother to Infant

Recruiting

• Conditions: Passive Transmission of Maternal and Infant Antibodies
• Interventions: Biological: sars-cov-2 vaccine or infection

• Registration Number: NCT05851911
• Lead Sponsor: Children's Hospital of Chongqing Medical University

Brief Summary

At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission. Therefore, this study assessed the changes of maternal passive transmission of COVID-19 antibodies by monitoring the specific antibodies of COVID-19 in young children; This will lay a foundation for further exploring the risk of COVID-19 infection in children and formulating immune prevention strategies.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-01
• Study First Submitted: 2023-05-09
• Study First Submitted QC: 2023-05-09
• Study First Posted: 2023-05-10
• Primary Completion: 2023-06-30
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-03
• Last Update Posted: 2023-07-06
• Study Completion: 2024-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Children aged 0-2;
2. No history of blood transfusion, chemotherapy, or related immunosuppressive therapy; No immune system related diseases;

Exclusion Criteria

Not willing to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control group 1	sars-cov-2 vaccine or infection	Mother not vaccinated with COVID-19 vaccine
Control group 3	sars-cov-2 vaccine or infection	The mother was vaccinated with COVID-19 vaccine before pregnancy, and was infected during pregnancy
Control group 2	sars-cov-2 vaccine or infection	The mother was vaccinated with COVID-19 vaccine before pregnancy, and was not infected during pregnancy
Experimental group	sars-cov-2 vaccine or infection	The mother was not vaccinated with COVID-19 vaccine before pregnancy, so she was infected during pregnancy

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 IgG	duration of time over which each participant could be 6-month to 12-month	ELISA detection of SARS-CoV-2 IgG antibody levels
SARS-CoV-2 neutralizing antibody	duration of time over which each participant could be 6-month to 12-month	detection the level of SARS-CoV-2 neutralizing antibody

Trial Locations

Locations (1)

Yuting Yang; 🇨🇳 Chongqing, Chongqing, China